Drug Trial Radar · NCT07746544
Study of Secutrelvir in Participants With COVID-19
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Aug 5, 2026
Primary completion
Jul 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.
Conditions
- COVID-19
Interventions
SecutrelvirDrug
Secutrelvir will be administered orally as a tablet.
PlaceboDrug
Placebo will be administered orally as a tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Resolution of 14 Protocol-defined Symptoms of COVID-19 Through Day 21Time frame: Baseline through Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Japanese Site 1
Multiple Locations, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.